Christopher S. Dodgson

Christopher S. Dodgson

Auto-generated profile, based on publicly available information

Christopher S. Dodgson

Faculty of Medicine, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
DNDaniel J. Nyberg
Daniel J. Nyberg
CDChristopher S. Dodgson
Christopher S. Dodgson
JAJohn M. Aalen
John M. Aalen
CEChristian H. Eek
Christian H. Eek
BBBjørn Bendz
Bjørn Bendz
ØLØyvind H. Lie
Øyvind H. Lie
Background: Aortic stenosis (AS) carries a high mortality risk if left untreated. Transcatheter aortic valve implantation (TAVI) has emerged as a primary treatment modality for many patients with severe AS. Observational data suggest that renin-angiotensin system (RAS) inhibitor use following TAVI are associated with lower risk, but with divergent reported effects and limited statistical power for specific cardiovascular outcome. This study aimed to assess the association between RAS inhibitor use and clinical outcomes after TAVI. Methods: A systematic literature search was conducted in EMBASE and PubMed. Eligible studies included those reporting on RAS inhibitor use in TAVI populations. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular mortality, myocardial infarction (MI), cerebrovascular events, and heart failure (HF) hospitalization. Results: Nine observational studies including 36,015 patients were included. RAS inhibitor use was associated with lower odds of all-cause mortality (OR 0.74, 95% CI 0.70– 0.78), cardiovascular mortality (OR 0.62, 95% CI 0.55–0.72), cerebrovascular events (OR 0.59, 95% CI 0.47–0.74), and HF hospitalization (OR 0.84, 95% CI 0.77–0.92). No clear association was observed for MI (OR 0.95, 95% CI 0.59–1.53). Conclusions: RAS inhibitor use was associated with favorable clinical outcomes following TAVI. However, these findings are based on observational data, which are subject to residual confounding. Randomized controlled trials are needed to clarify the clinical utility of RAS inhibitors in this setting.

8 May 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
CDChristopher S. Dodgson
Christopher S. Dodgson
HGHaakon K. Grøgaard
Haakon K. Grøgaard
ØLØyvind H. Lie
Øyvind H. Lie